Literature DB >> 20331603

GSK3beta: role in therapeutic landscape and development of modulators.

S Phukan1, V S Babu, A Kannoji, R Hariharan, V N Balaji.   

Abstract

Glycogen synthase kinase-3 beta (GSK3beta) is a multifunctional serine/threonine kinase which was originally identified as a regulator of glycogen metabolism. It plays a key role in the regulation of numerous signalling pathways including cellular process such as cell cycle, inflammation and cell proliferation. Over the last few years there is a considerable rise in the number of journals and patents publication by different workers worldwide. Many pharmaceutical companies are focusing on GSK3beta as a therapeutic target for the treatment of disease conditions. The present review is focused on signalling pathways of different disease conditions where GSK3beta is implicated. In this review, we present a comprehensive map of GSK3beta signalling pathways in disease physiologies. Structural analysis of GSK3beta along with molecular modelling reports from numerous workers are reviewed in context of design and development of GSK3beta inhibitors. Patent landscape of the small molecule modulators is profiled. The chemo space for small molecule modulators extracted from public and proprietary Kinase Chembiobase for GSK3beta are discussed. Compounds in different clinical phases of discovery are analysed. The review ends with the overall status of this important therapeutic target and challenges in development of its modulators.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20331603      PMCID: PMC2860202          DOI: 10.1111/j.1476-5381.2010.00661.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  108 in total

Review 1.  GSK-3: tricks of the trade for a multi-tasking kinase.

Authors:  Bradley W Doble; James R Woodgett
Journal:  J Cell Sci       Date:  2003-04-01       Impact factor: 5.285

2.  The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3.

Authors:  G Chen; L D Huang; Y M Jiang; H K Manji
Journal:  J Neurochem       Date:  1999-03       Impact factor: 5.372

3.  Sodium tungstate decreases the phosphorylation of tau through GSK3 inactivation.

Authors:  Alberto Gómez-Ramos; Jorge Domínguez; Delia Zafra; Helena Corominola; Ramon Gomis; Joan J Guinovart; Jesús Avila
Journal:  J Neurosci Res       Date:  2006-02-01       Impact factor: 4.164

4.  Essential roles for GSK-3s and GSK-3-primed substrates in neurotrophin-induced and hippocampal axon growth.

Authors:  Woo-Yang Kim; Feng-Quan Zhou; Jiang Zhou; Yukako Yokota; Yan-Min Wang; Takeshi Yoshimura; Kozo Kaibuchi; James R Woodgett; E S Anton; William D Snider
Journal:  Neuron       Date:  2006-12-21       Impact factor: 17.173

5.  Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP.

Authors:  Francesco Benedetti; Alessandro Serretti; Adriana Pontiggia; Alessandro Bernasconi; Cristina Lorenzi; Cristina Colombo; Enrico Smeraldi
Journal:  Neurosci Lett       Date:  2004-12-10       Impact factor: 3.046

6.  Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase.

Authors:  D P Hanger; K Hughes; J R Woodgett; J P Brion; B H Anderton
Journal:  Neurosci Lett       Date:  1992-11-23       Impact factor: 3.046

7.  BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents.

Authors:  Lian Mai; Richard S Jope; Xiaohua Li
Journal:  J Neurochem       Date:  2002-07       Impact factor: 5.372

8.  GSK-3-selective inhibitors derived from Tyrian purple indirubins.

Authors:  Laurent Meijer; Alexios-Leandros Skaltsounis; Prokopios Magiatis; Panagiotis Polychronopoulos; Marie Knockaert; Maryse Leost; Xiaozhou P Ryan; Claudia Alin Vonica; Ali Brivanlou; Rana Dajani; Claudia Crovace; Cataldo Tarricone; Andrea Musacchio; S Mark Roe; Laurence Pearl; Paul Greengard
Journal:  Chem Biol       Date:  2003-12

9.  Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas.

Authors:  S Sagae; K Kobayashi; Y Nishioka; M Sugimura; S Ishioka; M Nagata; K Terasawa; T Tokino; R Kudo
Journal:  Jpn J Cancer Res       Date:  1999-05

10.  Crosstalk between Cdk5 and GSK3beta: Implications for Alzheimer's Disease.

Authors:  Olivia Engmann; Karl Peter Giese
Journal:  Front Mol Neurosci       Date:  2009-05-29       Impact factor: 5.639

View more
  42 in total

1.  GSK3 controls axon growth via CLASP-mediated regulation of growth cone microtubules.

Authors:  Eun-Mi Hur; Byoung Dae Lee; Seong-Jin Kim; Wen-Lin Xu; Feng-Quan Zhou
Journal:  Genes Dev       Date:  2011-09-15       Impact factor: 11.361

2.  Structure-guided design of a highly selective glycogen synthase kinase-3β inhibitor: a superior neuroprotective pyrazolone showing antimania effects.

Authors:  Wenwen Chen; Irina N Gaisina; Hendra Gunosewoyo; Sam A Malekiani; Taleen Hanania; Alan P Kozikowski
Journal:  ChemMedChem       Date:  2011-07-12       Impact factor: 3.466

3.  Bi-phasic regulation of glycogen content in astrocytes via Cav-1/PTEN/PI3K/AKT/GSK-3β pathway by fluoxetine.

Authors:  Qiufang Bai; Dan Song; Li Gu; Alexei Verkhratsky; Liang Peng
Journal:  Psychopharmacology (Berl)       Date:  2017-02-24       Impact factor: 4.530

4.  Design of stapled α-helical peptides to specifically activate Wnt/β-catenin signaling.

Authors:  Hong-Kui Cui; Bing Zhao; Yehua Li; Ye Guo; Hao Hu; Lei Liu; Ye-Guang Chen
Journal:  Cell Res       Date:  2013-02-26       Impact factor: 25.617

5.  Syntheses, neural protective activities, and inhibition of glycogen synthase kinase-3β of substituted quinolines.

Authors:  Jianyu Lu; Izumi Maezawa; Sahani Weerasekara; Ramazan Erenler; Tuyen D T Nguyen; James Nguyen; Luxi Z Swisher; Jun Li; Lee-Way Jin; Alok Ranjan; Sanjay K Srivastava; Duy H Hua
Journal:  Bioorg Med Chem Lett       Date:  2014-06-04       Impact factor: 2.823

6.  Adenosine receptors: regulatory players in the preservation of mitochondrial function induced by ischemic preconditioning of rat liver.

Authors:  Filipe V Duarte; João A Amorim; Ana T Varela; João S Teodoro; Ana P Gomes; Rodrigo A Cunha; Carlos M Palmeira; Anabela P Rolo
Journal:  Purinergic Signal       Date:  2016-11-15       Impact factor: 3.765

7.  GSK-3β inhibition protects mesothelial cells during experimental peritoneal dialysis through upregulation of the heat shock response.

Authors:  K Rusai; R Herzog; L Kuster; K Kratochwill; C Aufricht
Journal:  Cell Stress Chaperones       Date:  2013-03-14       Impact factor: 3.667

8.  BDNF/TrkB Signaling as a Potential Novel Target in Pediatric Brain Tumors: Anticancer Activity of Selective TrkB Inhibition in Medulloblastoma Cells.

Authors:  Amanda Thomaz; Mariane Jaeger; Marienela Buendia; Victorio Bambini-Junior; Lauro José Gregianin; Algemir Lunardi Brunetto; André T Brunetto; Caroline Brunetto de Farias; Rafael Roesler
Journal:  J Mol Neurosci       Date:  2015-11-27       Impact factor: 3.444

9.  A GSK-3β inhibitor protects against radiation necrosis in mouse brain.

Authors:  Xiaoyu Jiang; Carlos J Perez-Torres; Dinesh Thotala; John A Engelbach; Liya Yuan; Jeremy Cates; Feng Gao; Robert E Drzymala; Keith M Rich; Robert E Schmidt; Joseph J H Ackerman; Dennis E Hallahan; Joel R Garbow
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-15       Impact factor: 7.038

10.  Glycogen Synthase Kinase 3β Inhibitor (2'Z,3'E)-6-Bromo-indirubin- 3'-Oxime Enhances Drug Resistance to 5-Fluorouracil Chemotherapy in Colon Cancer Cells.

Authors:  Kun-Ping Liu; Feng Luo; Si-Ming Xie; Li-Juan Tang; Mei-Xiang Chen; Xue-Fang Wu; Xue-Yun Zhong; Tong Zhao
Journal:  Chin J Cancer Res       Date:  2012-06       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.